RemovedRisk Factors
will impact professional society or practice guidelines, or coverage and reimbursement determinations from third-party payers, as we anticipate.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
materials with whom or which we are unfamiliar, and which may not perform as we anticipate, and could cause delays, downtime or other operational issues.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
utilize our tests, any enforcement action against the supplier by the FDA or any other regulatory authority in the jurisdictions in which our licensees and laboratory distribution partners are located could have an adverse impact on our business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
payments, which could adversely affect gross margins in future periods. If any of the foregoing were to occur, our business, financial condition, results of operations, cash flows, prospects, or stock price could be adversely affected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The reimbursement environment, particularly for molecular diagnostics, is continually changing and our efforts to broaden reimbursement for our tests with third-party payers may not be successful. Third parties, such as commercial health insurers and government programs, from whom we have received reimbursement may withdraw coverage or decrease the amount of reimbursement for our tests at any time and for any reason, or may otherwise adopt requirements, programs or policies that may restrict or adversely affect our business. In addition, in some cases, our tests or their uses
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Even if we are being reimbursed for our tests, third-party payers may review and adjust the rate of reimbursement, require patient cost-sharing, or stop paying for our tests. Government and commercial third-party payers continue to
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
policies or applicable laws and regulations, we may incur additional training and compliance costs; may, and from time to time do, receive inquiries, such as informal requests for documents, civil investigative demands, and subpoenas, from third-party payers or other third parties, including government entities; or may be held liable or otherwise responsible for such acts of non-compliance. Any of the foregoing could adversely affect our cash flow and financial condition.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
If FDA premarket clearance, approval develops an alternate approach to regulating LDTs, or de novo classification is required for any of if Congress enacts legislation giving FDA authority to regulate our existing current or future tests, LDTs, or for any components or materials we use in, or software that we or our customers use as part of, our tests, we may be forced to stop selling our tests or we may be required to modify claims for or make other changes to our tests while we or our suppliers work to obtain comply with FDA clearance, approval or de novo classification. requirements including, potentially, premarket authorization.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, to the extent that we are unable to retain our employees and they leave our company to join one of our competitors, we cannot assure you that any invention, non-disclosure or non-compete agreements we have in place will provide meaningful protection against a departing employee’s unauthorized use or disclosure of our confidential information, as further discussed in “—Risks Relating to our Intellectual Property—If we are not able to adequately protect our trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.”
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, because our licensees under our cloud-based distribution model also exclusively use such sole-sourced components to run the tests they develop based on our technology, and our laboratory distribution partners must use certain of such sole-sourced components in order to utilize our tests, any enforcement action against the supplier by the FDA or any other regulatory authority in the jurisdictions in which our licensees and laboratory distribution partners are located could have an adverse impact on our business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
While receiving such designations enables us to have increased interactions with FDA, this designation does not change the requirement that we cannot assure you that these designations will lead to accelerated review or approval demonstrate the safety and effectiveness of our regulatory submissions tests for Signatera. each
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our overall test volumes grew from approximately 2,066,500 2,496,100 to 2,496,100 3,064,600 and further to 3,064,600 3,525,500 tests processed during the years ended 2022, December 31, 2023, 2024, and 2024, 2025, respectively, and since 2009 in recent years we have launched over 15 launched, and intend to continue to launch, product offerings, enhancements, or and indications.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, any changes to our testing process may require us to use new or different suppliers or materials with whom or which we are unfamiliar, and which may not perform as we anticipate, and could cause delays, downtime or other operational issues.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
An important part of our business strategy is to expand and offer our tests internationally, either by providing our testing services directly or through our laboratory partners, or through our licensees under our Constellation cloud-based distribution model. internationally.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We currently operate laboratory facilities in Austin, Texas and in Texas, San Carlos, California, both of which process Panorama, Horizon, and Signatera tests, which together represent the significant majority of our revenues. Boulder, Colorado.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, we have limited experience forecasting our future financial performance from our new products in these industries that are newer to us, and our actual results may fall below our financial guidance or other projections, or the expectations of analysts or investors, which could cause the price of our common stock to decline.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
From time to time, we have and may in the future enter into transactions to acquire or dispose of businesses, products or technologies or to engage in other strategic transactions, such as our recent acquisition of certain reproductive health assets related to Invitae Corp.’s NIPT and carrier screening business. Foresight Diagnostics.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Similarly, certain results of the CIRCULATE-Japan study have recently been published, and we cannot assure you that such results will impact professional society or practice guidelines, or coverage and reimbursement determinations from third-party payers, as we anticipate.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, we have $80.4 $80.3 million of outstanding balance of the Credit Line balance, including accrued interest. interest, under our credit line with UBS.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We host the significant majority of these algorithms on a cloud-based cloud‑based software platform pursuant to an agreement with DNAnexus, Inc., or DNAnexus, and both we and our Constellation licensees access our algorithms through the DNAnexus platform.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Either Any of our these laboratories may be harmed or rendered inoperable, or samples could be damaged or destroyed, by natural or manmade disasters, including earthquakes, severe weather, flooding, power outages and contamination, including as a result of a health pandemic, which may render it difficult or impossible for us to perform our tests for some period of time.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We provide a comprehensive suite of products to improve patient care outcomes in three main areas of healthcare – oncology, women’s health, and organ health. We generate the majority of our revenues from the sale of Panorama, our non-invasive prenatal test (“NIPT”) and Horizon, our genetic carrier screening test. In addition to Panorama, our product offerings in women’s health include Fetal Focus, our noninvasive prenatal test for single-gene inherited conditions, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Anora, our test to help determine underlying reasons for occurrence of miscarriage, and Empower, our hereditary cancer screening test which we also offer through our oncology sales channel. In oncology, we offer Signatera, our personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer. We also offer Latitude, our blood-based MRD test for colorectal cancer that does not require a tumor tissue sample, as well as Altera, a comprehensive genomic profiling test to support treatment decisions and therapy selection.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The total consideration the Company expects to collect in exchange for the Company’s products is an estimate and may be fixed or variable. Consideration includes reimbursement from both patients and insurance carriers, adjusted for variable considerations related to disallowed cases, percent of patient responsibility collected, refunds and reserves, and is estimated using the expected value method. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio of relevant historical data to estimate variable consideration and total collections for the Company’s products. The Company constrains the estimated variable consideration when it determines it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In conjunction with the completion of the Company’s acquisition of Foresight Diagnostics in December 2025, we acquired a developed technology intangible asset for which we determined the acquisition date fair value using a multi-period excess earnings income approach valuation model that discounts expected future cash flows to present value. The expected future cash flows used in the valuation model include significant assumptions that form the basis of the forecasted results, principally the clinical revenue and related growth rate. These significant assumptions are forward-looking and could be affected by future economic and market conditions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
We currently provide a comprehensive suite of products in women’s health, oncology, and organ health, and our Constellation cloud-based platform. We generate a majority of our revenues from the sale of Panorama, our non-invasive prenatal test, or NIPT, as well as Horizon, our Carrier Screening test. In addition to Panorama and Horizon, our product offerings in women’s health include Spectrum Preimplantation Genetics, our Anora miscarriage test, and Vistara single-gene NIPT, as well as our Empower hereditary cancer screening test, which we also offer through our oncology sales channel. We also offer our Signatera molecular residual disease test for oncology applications, which we commercialize as a test run in our CLIA (as defined below) laboratories and offer on a research use only basis to research laboratories and pharmaceutical companies; and our Prospera organ transplant assessment tests.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
based distribution model, as a result of which our tests accessioned would decrease but our tests processed would remain unchanged.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We recognize revenues when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Product revenues are derived by performing genetic testing services and our performance obligation is complete when test results are delivered to a clinic or patient, who are considered the customer for such services. We enter into contracts with insurance carriers with primarily payment terms related to tests provided to the patients who have health insurance coverage. Insurance carriers are considered to be third-party payers on behalf of the patients, and the patients are considered as the customers who receive genetic test services. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. Further, we sell tests to a number of domestic and international laboratory partners and identify the laboratory partners as customers provided that there is a test services agreement between us and them.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 2022 (in thousands) Cash provided by (used in) operating activities $ 135,664 $ (246,955) $ (431,501) Cash provided by investing activities 137,624 168,498 330,338 Cash provided by financing activities 30,204 254,461 482,640 Net change in cash, cash equivalents and restricted cash 303,492 176,004 381,477 Cash, cash equivalents and restricted cash, beginning of period 642,095 466,091 84,614 Cash, cash equivalents and restricted cash, end of year $ 945,587 $ 642,095 $ 466,091
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
The increase was driven by a $48.3 attributable to an increase of $127.3 million increase in salary and related expenditures, which includes compensation expenditures (including a $24.2 $32.0 million increase in stock-based compensation expense, expense), a $25.7 million increase in lab and clinical trial related expenses, a $6.7 $19.4 million increase in consulting expenses, a $21.6 million increase in office related expenses, a $40.9 million increase in lab related and clinical trial expenses, a $2.8 $6.5 million net increase in office, facilities, facilities related expenses and a $4.3 million increase in travel and other expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The net loss of $190.4 $208.2 million includes $324.0 $413.5 million in non-cash charges resulting from $31.0 $41.8 million of depreciation and amortization, $274.4 $1.7 million of amortization of acquired intangibles, $354.4 million of stock-based compensation expense, $15.3 $20.2 million of non-cash lease expense, $1.0 million for amortization of debt discount and issuance cost, $0.5 million for foreign exchange adjustment, and $2.8 million of non-cash interest expense, offset by a $0.6 $3.2 million decrease change in amortization fair value of premiums warrants and accretion of purchase discounts on investment securities preferred stock and a $0.4 $1.4 million decrease in non-cash expense recovery.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was attributable to a $124.4 an increase of $212.6 million increase in salary and related expenditures, which includes compensation expenditures (including a $55.5 $41.1 million increase in stock-based compensation expense, expense), a $57.2 $25.2 million increase in consulting and legal expenses, a $8.9 $28.5 million increase in marketing costs, expenses, a $7.4 $8.7 million increase in travel expenses, related costs, a $7.4 $14.5 million increase in office related expenses, costs, a $16.5 $9.4 million increase in vendor expenses, a $30.6 million increase in legal related expenses, and a $1.2 $6.4 million net increase in facilities and other costs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest and other income Income tax benefit (expense) increased by $18.9 $60.6 million, or 77.6%, 8,722.9%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. a tax benefit from a partial release of the valuation allowance in connection with the acquisition of Foresight Diagnostics.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Operating liabilities resulted in had cash inflows of $31.2 $14.6 million resulting from a $13.2 $60.3 million increase in accrued compensation, a $0.8 million increase in accounts payable, a $40.3 $31.3 million increase in other accrued compensation, liabilities, and a $0.9 $2.8 million increase in deferred revenue, offset by a $16.8 $60.8 million decrease in deferred tax liability and a $19.8 million decrease in lease liabilities and a $6.4 million decrease in other accrued liabilities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Product revenues generated from our testing accounted for $2,295.8 million or nearly 100% of total revenues for the year ended December 31, 2025, compared to $1,685.1 million or 99% of total revenues for the year ended December 31, 2024, compared to 2024 and $1,068.5 million or 99% of total revenues for the year ended December 31, 2023 and $797.3 million or 97% of total revenues for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Operating assets had cash outflows of $29.1 $4.6 million resulting from a $35.9 $20.9 million increase in accounts receivable, inventory and a $4.0 $8.6 million increase in inventory, offset by a $10.8 million decrease in prepaid expenses and other assets, offset by a $20.7 million decrease in accounts receivable and a $4.2 million decrease in operating lease right-of-use assets.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The number of tests that we process is a key metric as it tracks overall volume growth, particularly as our laboratory partners may transition from sending samples to our laboratory to our cloud- cloud-based distribution model, as a result of which our tests accessioned would decrease but our tests processed would remain unchanged.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenues recognized from tests processed through our Constellation model, and from our strategic partnership agreements (which during the three years ended December 31, 2024, 2023 are reported in licensing and 2022 comprised BGI Genomics Co. other revenues.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest and other income increased by $18.9 $2.6 million, or 77.6%, 6.1%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. unrealized gains on warrant valuations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense decreased by $2.0 $6.6 million, 15.5%, 61.9%, in the year ended December 31, 2024 2025 compared to the same period in the prior year primarily as a result of the slight decrease in interest rate and due to the redemption of the Convertible Notes in October 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenues For the year ended December 31, 2024, revenues from customers outside the United States were $39.2 million, representing approximately 2% of total revenues for the year ended December 31, 2024. revenues.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new